Access cutting-edge breast cancer treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Access breast cancer specialists in Boston at no cost
This study follows strict safety protocols and ethical guidelines
All study-related breast cancer treatment provided free
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Sponsor: Novartis Pharmaceuticals
Check if you qualify for this breast cancer clinical trial in Boston, MA
If you're searching for breast cancer treatment options in Boston, MA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.